Research programme: cancer therapies - Delphian Pharmaceuticals
Latest Information Update: 20 Sep 2011
At a glance
- Originator Delphian Pharmaceuticals
- Mechanism of Action Tubulin modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 Jul 2007 Preclinical trials in Cancer in USA (unspecified route)